View Post

Savvy Cooperative: Paid Opportunity for Locally Advanced or Metastatic Pancreatic Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Eligibility Criteria: Adults who have been diagnosed with pancreatic cancer Verification of diagnosis will be required to participate Ages 18 years or older Have experienced symptoms in the past 30 days Currently living in the United States Able to read, write, and speak in English Details: 60-minute interview From a home computer Receive: $100 Link: https://gigs.savvy.coop/pancreatic-c/?r=44951 Why Sign Up? …

View Post

FibroGenesis Reports Positive Preclinical Data in Pancreatic and Breast Cancer Using “Universal Acting” Fibroblast Based Immunotherapy

In Clinical Studies News by Barbara Jacoby

Source: FibroGenesis From: biospace.com FibroGenesis, a clinical stage company developing fibroblast-based therapeutic solutions for unmet medical needs, announced today new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer. Company scientists successfully replicated the process by which cancer coaxes fibroblasts to support its growth.  By manipulating these …

View Post

FibroGenesis Reports Positive Preclinical Data in Pancreatic and Breast Cancer Using “Universal Acting” Fibroblast Based Immunotherapy

In In The News by Barbara Jacoby

Source: FibroGenesis From: prnewswire.com Novel Approach Successfully Induces Regression of Established Tumors by Focusing Immunotherapy to Target “Achilles Heel” of Cancer FibroGenesis, a clinical stage company developing fibroblast-based therapeutic solutions for unmet medical needs, announced today new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer. Company …

View Post

DA grants orphan drug designation to OBI-999 for pancreatic cancer

In Clinical Studies News by Barbara Jacoby

From: healio.com The FDA granted orphan drug designation to the antibody-drug conjugate OBI-999 for the treatment of pancreatic cancer, according to a press release from the agent’s manufacturer. OBI-999 (OBI Pharma) targets Globo H, a glycolipid antigen expressed in up to 15 epithelial cancers. Preclinical xenograft animal models of pancreatic, lung, gastric and breast cancers showed OBI-999 induced profound tumor …

View Post

Updated Genetic Screening Guidelines Published by National Comprehensive Cancer Network Feature Emerging Evidence on Personalized Medicine

In In The News by Barbara Jacoby

Newly updated and expanded NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic clarify who should be tested for cancer-causing genetic mutations. Experts caution about risks of direct-to-consumer genetic testing and stress the importance of genetic counseling. The National Comprehensive Cancer Network® (NCCN®) today announced publication of the newest genetic risk assessment recommendations for breast, ovarian and pancreatic cancers. …

View Post

World’s First Clinical Trial to Ease Pain of Cancer Patients

In Clinical Studies News by Barbara Jacoby

Dr. Yaacov Richard Lawrence, a London-born and educated doctor, is part of a unique team of Radiation Oncology specialists at Sheba Medical Center, conducting the world’s first  clinical trial and study of targeted radiation treatments into the solar plexus (the main abdominal artery), to relieve excruciating pain and prolong the lives of critically ill pancreatic cancer patients. Other members of the …

View Post

New guideline clarifies role of radiation therapy in pancreatic cancer treatment

In In The News by Barbara Jacoby

First-of-its-kind clinical guideline from leading radiation oncology society discusses radiation dosing, conventional versus stereotactic radiation and mitigating side effects A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations on the use of radiation therapy to treat patients diagnosed with pancreatic cancer, including when radiation treatments are appropriate, as well as the optimal dosing, timing and …

View Post

Pancreatic cancer patient in partial remission after experimental drug treatment

In Clinical Studies News by Barbara Jacoby

By: Ronda Wendler From: mdanderson.org Allison Lippman was 30 years old when she was diagnosed with stage 4 pancreatic cancer. A new drug that targets her cancer’s genetic mutation has shrunk her tumors in half. Just before she was diagnosed with pancreatic cancer, Allison Lippman was on top of the world. She’d just celebrated her 30th birthday, been promoted at …

View Post

CRUK tests drug combo for advanced pancreatic cancer

In Clinical Studies News by Barbara Jacoby

From: pharmaphorum.com Cancer Research UK has announced it will study Plexxikon’s dual kinase inhibitor PLX7486 in combination with gemcitabine in advanced pancreatic cancer as part of its Combinations Alliance. The novel combination of drugs targets the process of nerve invasion, observed in over 80% of pancreatic ductal adenocarcinoma (PDAC) and is associated with tumour spread and severe pain. The PAGoDA …